New Perspectives in Achieving Blood Pressure Control: Focus on New Sartan — Azilsartan Medoxomil

A.V. Savustyanenko

Abstract


Azilsartan medoxomil is a new member of the class angiotensin receptor blockers (sartans). It possesses the unique ability to strongly bind to the AT1 receptors and dissociate slowly from them that leads to a powerful inhibition of the renin-angiotensin-aldosterone system and the development of pronounced hypotensive effect. The starting dose of azilsartan medoxomil in the most patients is 40 mg 1 time per day, maximum — 80 mg 1 time per day. Effectiveness of azilsartan medoxomil in the usual dose exceeds the effectiveness of ramipril and several other sartans (candesartan, valsartan). Activity of the maximum dose of the drug exceeds that of olmesartan. Azilsartan medoxomil is well tolerated; side effects are rare and are of mild/moderate severity. Currently, the preparation is recommended as a monotherapy or in combination with other drugs for the treatment of essential hypertension in adults.

Keywords


azilsartan medoxomil; hypertension

References


Barrios V., Escobar C. Азилсартана медоксомил в лечении артериальной гипертензии: наиболее эффективный блокатор рецепторов ангиотензина? // Почки. — 2014. — № 1 (7). — С. 85-98.

Balakumar P., Mahadevan N. Azilsartan: A Novel Angiotensin-II Type 1 Receptor Blocker for Treating Hypertension // International Journal of Recent Advances in Pharmaceutical Research. — 2011. — Vol. 2. — P. 11-13.

Jones J.D., Jackson S.H., Colquitt C. Azilsartan alone and in combination for the treatment of hypertension — clinical utility and patient considerations // Research Reports in Clinical Cardiology. — 2013. — Vol. 4. — P. 125-133.

Azilsartan Medoxomil (Edarbi): The Eighth Angiotensin II Receptor Blocker / Jones J.D., Jackson S.H., Agboton C., Martin T.S. // P&T. — 2011. — Vol. 36, № 10. — P. 634-636, 638-640.

Miao Hu T., Tomlinson B. Update on the Use of Angiotensin Receptor Blockers in Hypertension: A Focus on Azilsartan Medoxomil // Journal of The Society of Physicians of Hong Kong. — 2014. — Vol. 6, № 3. — P. 34-36.

Antihypertensive efficacy of the angiotensin receptor blocker azilsartan medoxomil compared with the angiotensin-converting enzyme inhibitor ramipril / Bönner G., Bakris G.L., Sica D. et al. // J. Hum. Hypertens. — 2013. — Vol. 27, № 8. — P. 479-486.

EARLY Treatment with azilsartan compared to ACE-inhibitors in anti-hypertensive therapy — rationale and design of the EARLY hypertension registry / Gitt A.K., Baumgart P., Bramlage P. et al. // BMC Cardiovascular Disorders. — 2013. — Vol. 13, № 46.

Comparison of the efficacy and safety of azilsartan with that of candesartan cilexetil in Japanese patients with grade I-II essential hypertension: a randomized, double-blind clinical study / Rakugi H., Enya K., Sugiura K., Ikeda Y. // Hypertens. Res. — 2012. — Vol. 35, № 5. — P. 552-558.

Comparison of the novel angiotensin II receptor blocker azilsartan medoxomil vs valsartan by ambulatory blood pressure monitoring / Sica D., White W.B., Weber M.A. et al. // J. Clin. Hypertens. (Greenwich). — 2011. — Vol. 13, № 7. — P. 467-472.

The comparative effects of azilsartan medoxomil and olme-sartan on ambulatory and clinic blood pressure / Bakris G.L., Sica D., Weber M. et al. // J. Clin. Hypertens. (Greenwich). — 2011. — Vol. 13, № 2. — P. 81-88.

Effects of the angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertension / White W.B., Weber M.A., Sica D. et al. // Hypertension. — 2011. — Vol. 57, № 3. — P. 413-20.

Baker W.L., White W.B. Azilsartan medoxomil: a new angiotensin II receptor antagonist for treatment of hypertension // Ann. Pharmacother. — 2011. — Vol. 45, № 12. — P. 1506-1515.

Stamler R. Implications of the INTERSALT Study // Hypertension. — 1991. — Vol. 17 (Suppl. 1). — P. I16-I20.

National High Blood Pressure Education Program Coordinating Committee. Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure / Chobanian A.V., Bakris G.L., Black H.R. et al. // Hypertension. — 2003. — Vol. 42. — P. 1206-1252.

http://edarbyclorrx.com/hypertension-overview




DOI: https://doi.org/10.22141/2224-1485.4.36.2014.82734

Refbacks

  • There are currently no refbacks.


Copyright (c) 2016 HYPERTENSION

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

© Publishing House Zaslavsky, 1997-2018

 

 Яндекс.МетрикаSeo анализ сайта Рейтинг@Mail.ru